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Abstract
Purpose—Mutations in the PI3-kinase (PI3K) pathway occur in 16% of patients with pancreatic 
neuroendocrine tumors (PanNETs), which suggests that these tumors are an exciting setting for 
PI3K/AKT/mTOR pharmacological intervention. Everolimus, an mTOR inhibitor, is being used to 
treat patients with advanced PanNETs. However, resistance to mTOR targeted therapy is emerging 
partially due to the loss of mTOR-dependent feedback inhibition of AKT. In contrast, the response 
to PI3K inhibitors in PanNETs is unknown.
Experimental Design—In the present study, we assessed the frequency of PI3K pathway 
activation in human PanNETs and in RIP1-Tag2 mice, a preclinical tumor model of PanNETs, and 
we investigated the therapeutic efficacy of inhibiting PI3K in RIP1-Tag2 mice using a combination 
of pan (GDC-0941) and p110α selective (GDC-0326) inhibitors and isoform specific PI3K kinase-
dead mutant mice.
Results—Human and mouse PanNETs showed enhanced pAKT, pPRAS40 and pS6 positivity 
compared to normal tissue. While treatment of RIP1-Tag2 mice with GDC-0941 led to reduced 
tumor growth with no impact on tumor vessels, the selective inactivation of the p110α PI3K 
isoform, either genetically or pharmacologically, reduced tumor growth as well as vascular area. 
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Furthermore, GDC-0326 reduced the incidence of liver and lymph node (LN) metastasis compared 
to vehicle treated mice. We also demonstrated that tumor and stromal cells are implicated in the 
anti-tumor activity of GDC-0326 in RIP1-Tag2 tumors.
Conclusion—Our data provide a rationale for p110α selective intervention in PanNETs and 
unravel a new function of this kinase in cancer biology through its role in promoting metastasis.
Introduction
Neuroendocrine tumors (NETs) comprise a family of malignancies that arise from 
neuroendocrine cells in different body locations (1). Fully-differentiated NETs are further 
classified as either carcinoid or pancreatic. In particular, pancreatic neuroendocrine tumors 
(PanNETs) have a low incidence rate (less than 0.5%) (2) but account for the second most 
prevalent malignancy of the pancreas (2–4). Despite being rare, PanNETs are often 
diagnosed at an advanced stage with a high proportion exhibiting metastatic lesions. The 
poor clinical response to current treatments, particularly after failure to respond to 
chemotherapy (5), highlights the need for new therapeutic options in the management of this 
tumor type.
PI3Ks are a family of lipid kinases composed of eight catalytic isoforms and grouped in 
three classes on the basis of structure, regulation, and preferred lipid substrate (6, 7). 
Mammals have four catalytic class I PI3K isoforms (p110α, p110β, p110γ and p110δ) 
which are constitutively bound to a regulatory subunit (6, 7). The AKT and mTOR axis is 
the major downstream hub of class I PI3K signaling, and mediates multiple cellular 
functions, including cell metabolism, growth, proliferation, migration, and survival (8).
Activation of the PI3K pathway is frequently observed in human cancer, as a consequence of 
multiple molecular alterations, including mutations (PIK3CA, AKT1, PTEN, RAS), gene 
amplification (PIK3CA, AKT1, AKT2), loss of expression of tumor suppressors (PTEN, 
TSC2 and INPP4B), and oncogenic tyrosine kinase signaling (7, 9). PI3Ks also mediate 
tumor stromal functions, such as angiogenesis and recruitment of inflammatory cells (7, 10). 
A recent whole exome sequencing study has revealed mutations in PI3K pathway genes in 
16% of patients with PanNETs (11); including mutations in PIK3CA, PTEN,and TSC2. In 
addition to mutations, PTEN and TSC2 expression levels are downregulated in 75% of 
PanNETs and is associated with reduced disease-free progression and overall survival (12). 
Furthermore, high activation of mTOR downstream effectors, such as pS6K and pS6 is 
associated with adverse clinical outcomes in PanNETs (13). Taken together, these data 
suggest that the PI3K/AKT/mTOR pathway might be functionally relevant in the 
progression of PanNETs and indicate that it is an exciting setting to test PI3K/AKT/mTOR 
pharmacological intervention. Indeed, everolimus, an mTOR allosteric inhibitor is currently 
being used to treat patients with advanced PanNETs (5, 14, 15). A phase II clinical trial has 
showed efficacy of everolimus in metastatic PanNETs after failure of chemotherapy (5, 15). 
More recently, the results of a first-line phase III trial with everolimus (RADIANT-3) have 
emerged (16). While the data did not show statistical differences, it is noteworthy that 
everolimus treatment resulted in a median overall survival of 44 months with a clinically 
substantial improvement of at least 6 months vs. placebo (16). A mechanism of adaptive 
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resistance to mTOR inhibitor has been described, involving loss of mTOR-dependent 
feedback inhibition of AKT (17–19). These data suggest that targeting PI3K, the upstream 
signal, may overcome this feedback loop. However, it is not currently known whether PI3K 
intervention in PanNETs results in an improved clinical outcome.
One of the most widely used models to study PanNETs is the genetically engineered RIP1-
Tag2 model in which mice synchronously progress from incipient neoplasia to invasive 
carcinomas (20). Tumors of RIP1-Tag2 mice develop from the β-cells of the pancreatic of 
Langerhans islets as a result of expression of the SV40 large and small T-antigen under the 
control of the insulin promoter (20). Some evidence suggests that the PI3K pathway might 
be relevant during tumor progression in the RIP-Tag2 model (2). While specific inhibitors of 
mTOR have been tested in this preclinical model of PanNET progression, the effect of 
targeting PI3K isoforms is unknown (2).
Motivated by the observation that the PI3K pathway is often mutated and activated in 
PanNETs, we sought to investigate the therapeutic benefit of inhibiting the PI3K pathway in 
the RIP1-Tag2 mouse model. Here, we report that selective inactivation of the p110α 
isoform is sufficient to block RIP1-Tag2 tumor progression and metastasis. We demonstrate 
that inhibition of p110α impacts on tumor cells by inducing cell death and on the tumor 
microenvironment by compromising vessel growth.
Material and Methods
Mice
Mice were kept in individually-ventilated cages and cared for according to the guidelines 
and legislation of the Catalan DARP (Departament d’ Agricultura, Ramaderia i Pesca). 
Heterozygous p110αD933A/WT (Ref (21)), p110βD931A/WT (Ref (22)), and p110δD910A/WT 
(Ref (23)), RIP1-Tag2 (Ref(20)) were backcrossed onto the C57/BL6 background for >10 
generations and WT littermates used as controls.
Cell lines
βTC3 and βTC4 cells were derived from RIP1-Tag2 mouse tumors (20). They were 
generated in Douglas Hanahan’s laboratory in 1988 as previously described (24). Briefly, β 
cells were isolated by mechanical disruption from the tumor capsule and plated in 12-well 
plates in the presence of DMEM medium containing 15% horse serum, 2.5% fetal bovine 
serum and 25 mM glucose (24). We authenticated these cells every time that they were 
thawed by Insulin, large T antigen immunofluorescence and growth pattern and morphology.
Therapeutic treatments
RIP1-Tag2 mice were treated daily by oral gavage starting at 12 weeks of age until 14 weeks 
of age with GDC-0941 (100 mg/kg/day), GDC-0326 (12 mg/kg/day) or vehicle (0.5% (w/v) 
methylcellulose and 0.2% (w/v) polysorbate 80 in de-ionized water).
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The presence of tumor cells in the liver or LNs was assessed by T-antigen immunostaining 
in either OCT embedded and frozen or fixed in 4% PFA and embedded in paraffin. The 
incidence of liver/LN metastasis was determined by scoring for presence or absence in each 
animal from a minimum of ten mice per group.
Statistical Analysis
Means were compared between two groups using nonparametric Mann Whitney’s test and 
parametric t-student. For evaluating the Kaplan-Meier survival curves, Log Rank test was 
used. In all cases *p < 0.05, **p < 0.01, and ***p < 0.001 were considered statistically 
significant.
Results
PI3K pathway activation in human and mouse PanNETs
In order to study the frequency of PI3K pathway activation in human PanNETs, we stained 
tissue samples from normal pancreas (n=15) and tumors (n=40) from patients diagnosed 
with neuroendocrine islet cell tumors, with the phospho-specific antibodies pAKT (S473), 
pPRAS40 (T246) and pS6 (S240/4) that are widely used makers of PI3K/AKT/mTOR 
pathway activation. Normal tissue showed positive staining in the acinar cells of the 
pancreas and a lack of staining in the endocrine islet cells or Langerhans islets (Fig. 1A, left 
panel). In contrast, in the tumor cohort we found a variety of immunoreactivity across the 
samples ranging from negative to positive (Figure 1A, right panels). We found pAKT (S473) 
and pPRAS40 (T246) positivity in 15/40 cases (37.5%), and pS6 (S240/4) positivity in 
16/40 cases (40%) (Fig. 1B). This finding was consistent with the heterogeneous nature of 
this disease, since many genetic drivers have been found to be responsible for the 
pathogenesis of human PanNETs.
To further explore our results in a preclinical model of PanNET, we took advantage of the 
RIP1-Tag2 mouse model of neuroendocrine tumor progression (from normal islet to invasive 
carcinoma). We speculated that the PI3K/AKT/mTOR pathway might be gradually activated 
during this process. Therefore, we stained pAKT (S473), pPRAS40 (T246), and pS6 
(S240/4) in normal islets, encapsulated low-grade tumors, and invasive carcinomas from the 
RIP1-Tag2 mouse model. Consistent with our findings in human samples, exocrine 
structures were positive for all three stainings, while the endocrine islets were largely 
negative (Fig. 1C, top panels). Encapsulated tumors exhibited positivity for pAKT (S473), 
pPRAS40 (T246), and pS6 (S240/4) markers (Fig. 1C, middle panels). Remarkably, invasive 
tumors showed enhanced staining for all of the three markers of PI3K/AKT/mTOR pathway 
activation (Fig. 1C, bottom panels). Together, our results confirm the importance of the 
PI3K/AKT/mTOR signaling in the human pathology and during the progression of the 
PanNETs (13).
We next asked whether over-activation of the PI3K pathway in the human PanNET cohort 
and in the RIP1-Tag2 mouse tumor model was caused by loss of PTEN expression or by 
oncogenic activatory mutations in PIK3CA, the gene encoding p110α, two common 
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mechanisms by which PI3K signaling is activated in transformed cells (7). The majority of 
human tumors analyzed were positive for PTEN expression (Supplementary Fig. 1A and B). 
In the same line, encapsulated and invasive RIP1-Tag2 tumors, as well as βTC3 cells, a cell 
line derived of the RIP1-Tag2 model (25), showed positivity for PTEN (Supplementary Fig. 
1C and D). Analysis of the three most prevalent hotspot mutations of Pik3ca (E542K/E545K 
and H1047R) by Sanger sequencing in βTC3 cells revealed that these cells did not contain 
mutated p110α (Supplementary Fig. 1E). Together these results suggest that over-activation 
of the PI3K pathway in the RIP1-Tag2 mouse model is not induced by either loss of 
expression of PTEN or oncogenic mutations in PIK3CA. Given that the SV40 T-antigens 
induced-PanNETs progressively activate EGFR signaling pathway, it is tempting to 
speculate that this mechanism accounts for activation of PI3K and its downstream effectors 
in the RIP1-Tag2 mouse model (2). Another possibility is that SV40 small T-antigen 
stimulates phosphorylation of AKT in a PP2A-dependent manner, as it has been reported in 
other systems (26).
Inhibition of PI3K blocks tumor progression in RIP1-Tag2 mice
Next, we tested the effect of inhibiting the PI3K signaling pathway in vivo by using the 
GDC-0941 compound (27), which inhibits p110α/β/γ and δ. As shown in Fig. 2A, 
administration of GDC-0941 to RIP1-Tag2 mice resulted in reduced AKT phosphorylation, 
suggesting inhibition of PI3K signaling. To test the impact of GDC-0941 on tumor 
progression, we focused on the initial onset of malignant progression (20, 25) 
(Supplementary Fig. 2A). We initiated daily treatment of 12-week-old RIP1-Tag2 animals, 
which corresponds to the timing of early tumor initiation, and continued the treatment until 
14 weeks of age, when end-stage tumors are already present. Tumor-bearing RIP1-Tag2 
mice treated with GDC-0941 showed a significant improvement in lifespan (Fig. 2B) with a 
trend towards decreased tumor burden (Fig. 2C) compared to control age-matched vehicle-
treated animals.
We sought to analyze phenotypic markers of PI3K inhibition, including the proliferative 
status of tumor cells, microhaemorrhaging and vascular density of the tumor. GDC-0941 did 
not modify tumor cell proliferation in vivo (as assessed by Ki67 immunostaining; 
Supplementary Fig. 2B,C) indicating that PI3K signaling does not mediate this biological 
function in PanNETs. We validated this result in two cell lines derived of the RIP1-Tag2 
model, the βTC3 and βTC4 cells (25). Pre-treatment with pan or isoform selective PI3K 
inhibitors did not alter βTC3 and βTC4 cell proliferation (Supplementary Fig. 2D-F). We 
further demonstrated the lack of effect of PI3K inhibition on cell proliferation of βTC3 and 
βTC4 cells by using BKM120, another pan-PI3K inhibitor (Supplementary Fig. 2E,F) (28).
In vivo treatment with GDC-0941 led to a minor reduction in the number of red tumors (Fig. 
2D,E), suggesting an impact on tumor vasculature, in accordance with previous findings (10, 
29). However, histological analysis of tumor vessels by CD31 staining and quantification 
showed that GDC-0941 did not modify vessel area (Fig. 2F,G).
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Genetic inactivation of p110α impairs tumor growth in RIP1-Tag2 mice
To gain insight into the biochemical role of PI3K in PanNETs, we next studied whether 
different PI3K isoforms have selective roles in mediating PI3K signaling in the RIP1-Tag2 
tumor model. βTC3 cells expressed p110α, p110β and p110δ, but not p110γ (Fig. 3A). 
Treatment of βTC3 cells with GDC-0941 and with GDC-0326, a newly developed small 
molecule inhibitor with selectivity for p110α inhibitor (Supplementary Fig. 3A) (30) 
reduced AKT phosphorylation (Fig. 3B), to a similar extent as BYL719, another selective 
p110α inhibitor (Supplementary Fig. 3B) (31). Conversely, the p110β selective inhibitor 
(TGX-221) or p110δ selective inhibitor (IC87114) failed to reduce pAKT levels in these 
cells (Fig. 3B), suggesting that the p110α PI3K isoform is principally responsible for 
activation of AKT in the RIP1-Tag2 mouse model.
To further address the role of individual p110 isoforms in tumor formation in the RIP1-Tag2 
mice, we took advantage of knock-in (KI) mouse lines in which the endogenous p110α/β/δ 
isoforms have been converted to kinase-dead proteins (p110αD933A, p110βD931A, and 
p110δD910A) (21–23) by introducing a germline point mutation in the ATP-binding DFG 
motif of Pik3ca (gene encoding p110α), Pik3cb (gene encoding p110β), and Pik3cd (gene 
encoding p110δ Fig. 3C-E). These constitutive mutant mice mimic, to some extent, the 
effects of systemic administration of isoform selective PI3K inhibitors (22, 32, 33). Given 
that homozygous p110αD933A/D933A and p110βD931A/D931A KI mice die during embryonic 
development (21, 22), we crossed heterozygous p110αD933A/WT, p110βD931A/WT, and 
p110δD910A/WT (WT is the wild-type allele; Fig. 3C-E) with RIP1-Tag2 mice (further 
referred to as RIP1-Tag2-p110αD933A/WT, RIP1-Tag2-p110βD931A/WT, and RIP1-Tag2-
p110δD910A/WT). Of note, the heterozygous p110 kinase-dead mutants have been crucial in 
understanding the physiological roles of these isoforms as they show an intermediate 
phenotype in cultured cells and in mice compared to homozygous mutants, indicating a 
dose-dependent activity of these PI3K isoforms (22, 32, 33).
To evaluate the effects of individual p110 isoforms on tumor initiation and growth, RIP1-
Tag2-p110αD933A/WT, RIP1-Tag2-p110βD931A/WT, and RIP1-Tag2-p110δD910A/WT mice 
were sacrificed at 14 weeks of age and compared to their WT littermates. No difference in 
overall survival was observed upon heterozygous genetic inactivation of p110α, p110β or 
p110δ, (Supplementary Fig. 3C). Instead, total mean tumor volume was blunted (by 
approximately 40%) upon inactivation of p110α (Fig. 3F) with no difference upon 
inactivation of p110β (Fig. 3G) and p110δ (Fig. 3H). Analysis of downstream PI3K 
signaling in individual RIP1-Tag2 tumors revealed reduced AKT phosphorylation and 
reduced mTORC1 signaling in RIP1-Tag2-p110αD933A/WT (Fig. 3I,J). Conversely, 
inactivation of p110β and p110δ did not reduce AKT or S6 phosphorylation (Fig. 3K-N). 
Taken together, our data suggest that p110α, but not p110β and p110δ, activity contributes 
to PanNET progression in the RIP1-Tag2 mouse model. The lack of significance in tumor 
burden between wild-type and p110αD933A/WT tumors is likely due to the heterozygous 
approach used.
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p110α gene inactivation blocks tumor angiogenesis
Phenotypic analysis of individual tumors revealed that constitutive heterozygous genetic 
inactivation of p110α, p110β and p110δ did not alter the number of proliferative tumor cells 
(Supplementary Fig. 3D). Given the relevant role of p110α in tumor angiogenesis (29), we 
hypothesized that the anti-tumor activity of p110α inactivation may relate to alterations in 
the tumor vasculature. Indeed, p110αD933A/WT tumors exhibited reduced vascular area (Fig. 
4A,B). Consistent with no role of p110β and p110δ in developmental angiogenesis (33), 
RIP1-Tag2-p110βD931A/WT and RIP1-Tag2-p110δD910A/WT had a similar CD31 positive 
area compared to their WT littermates (Fig. 4C-F). To further demonstrate a role for p110α 
in tumor angiogenesis, we macroscopically assessed the number of hypervascularized “red 
islets” with dilated, micro-hemorrhaging vasculature. RIP1-Tag2-p110αD933A/WT 
pancreases showed a reduced number of red islets (Supplementary Fig. 4A). Interestingly, 
RIP1-Tag2-p110βD931A/WT and RIP1-Tag2-p110δD910A/WT tumors also showed reduced 
number of red islets (Supplementary Fig. 4B,C), and although the reason for this effect is not 
clear, it might be related to additional stromal functions previously attributed to these 
isoforms (10, 34). Taken together, our data suggest that the anti-tumor activity observed 
upon inactivation of p110α is due to its effect on vessel growth.
Selective pharmacological inactivation of p110α leads to a positive therapeutic response
The genetic analysis using PI3K kinase-dead mice promoted us to further investigate the 
selective inhibition of p110α using a pharmacological strategy, which allows the inhibition 
of this isoform at a greater level. We first tested whether inhibition of p110α alone was 
sufficient to abrogate PI3K/AKT signaling both in vitro and in vivo. Treatment with 
GDC-0326 abolished AKT phosphorylation in βTC3 cells (Fig. 3B) and in RIP1-Tag2 
tumors (Fig. 5A). Next, tumor-bearing RIP1-Tag2 mice were treated with GDC-0326 from 
week 12 of age to week 14 of age. A significant improvement in the lifespan of RIP1-Tag2 
mice was observed upon GDC-0326 treatment compared to control age-matched mice 
treated with vehicle (Fig. 5B). Furthermore, GDC-0326 produced a significant impairment 
in tumor growth (approximately 60% reduction; Fig. 5C). To further investigate the response 
to selective p110α inhibition, we assessed incidence of tumor dissemination and metastasis 
in peripancreatic LNs and liver. The presence of tumor cells in LNs and liver was detected 
by H&E and T antigen immunostaining (Fig. 5D). Remarkably, none of the GDC-0326 
treated RIP1-Tag2 mice showed positivity for Anti-T antigen in the liver (Fig. 5E,F). 
Quantification of incidence of microscopic LN metastasis revealed that the presence of 
tumor cells in LNs was reduced by four times in GDC-0326-treated animals compared to 
controls (Fig. 5E,F). Furthermore, from those mice that showed LN infiltration, the average 
number of positive nodes was also decreased upon selective inhibition of p110α (1.6±0.78 
vs. 1 ± 0 number of positive T antigen LN /animal). Taken together, our data suggest that 
selective inhibition of p110α in the RIP1-Tag2 mouse model blocks tumor cell 
dissemination.
GDC-0326 blocks tumor growth principally by inhibiting angiogenesis
Analysis for phenotypic markers of the PI3K inhibition revealed that GDC-0326 did not 
alter tumor cell proliferation in vivo (Supplementary Fig. 5A,B). Conversely, inhibition of 
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p110α led to reduced number of “red islet” (Fig. 6A) and decreased vascular area (Fig. 
6B,C) suggesting anti-angiogenic activity of GDC-0326. The impact of PI3K inhibitors on 
tumor vessels has been attributed to reduced VEGF levels and to direct cell-autonomous 
effects on endothelial cells (ECs) (10, 29). Analysis of mRNA levels of VEGF in RIP1-Tag2 
tumors revealed no difference between vehicle and GDC-0326 treated tumors 
(Supplementary Fig. 5C). Instead, incubation of mouse lung ECs with GDC-0326 resulted in 
reduced cell migration with no effect on cell proliferation and survival (Supplementary Fig. 
6), as previously shown (33, 35). Together these data suggest that the anti-vascular effects 
induced by GDC-0326 in RIP1-Tag2 mice are mainly EC-mediated.
Previous data from our laboratory have shown that stromal inhibition of p110α results in 
reduced vessel function, which in turn leads to tumor cell death (29). RIP1-Tag2 mice 
treated with GDC-0326 showed an overall increase in tumor cell-death assessed by TUNEL 
staining (Fig. 6D,E). We assessed whether this apoptotic effect was cell intrinsic or stromal 
mediated. Pre-treatment of βTC3 cultured cells with GDC-0326 resulted in increased 
apoptosis (Fig. 6F). Of note, pre-treatment of βTC3 cells with p110β and p110δ selective 
inhibitors did not induce cell death (Fig. 6F). These data suggest that treatment with 
GDC-0326 leads to tumor cell-death by at least partially stimulating apoptosis directly on 
these cells. We next assessed whether GDC-0326 pro-apoptotic effects were enhanced in 
low nutrients conditions. Treatment of βTC3 and βTC4 cells with GDC-0326 and BYL719 
under low glucose conditions also stimulated cell death (Supplementary 6D,F) to a similar 
extent than normal growing conditions. Taken together, these data demonstrate tumor cell 
intrinsic cytotoxic properties of PI3K inhibitors in βTC3 and βTC4 cells, albeit at low 
levels. Our data further suggest that tumor-cell death induced by selective inhibition of 
p110α in vivo is principally mediated by reduced vascularity.
Discussion
PanNETs are considered rare tumors with low incidence, but with high prevalence among 
pancreatic tumors (1, 3, 36). This type of neoplasm comprises a highly heterogeneous 
disease, which has complicated the development of targeted therapies. Recent advances in 
the understanding of molecular alterations in PanNETs have allowed the identification of the 
relevant mechanisms involved in the pathogenesis of this neoplasm. The PI3K/AKT/mTOR 
pathway is mutated in 16% of PanNETs, and therefore presents an exciting therapeutic 
target (11). PIK3CA is frequently amplified or somatically mutated in solid tumors (7), 
which has encouraged a tremendous drug development effort to target this isoform. Indeed, 
there are numerous ongoing clinical trials assessing different compounds to target the PI3K 
pathway, including those that specifically interfere with the p110α isoform (9, 37). However, 
it is still under debate which type of inhibitor (pan-PI3K inhibitor vs. isoform-selective PI3K 
inhibitor) would offer a better clinical outcome. Pan-PI3K inhibitors may exhibit higher 
toxicity, especially when combined with other agents. Isoform selective inhibitors may 
instead show less efficacy or increased compensations by other PI3K isoforms (7, 9). Using 
a combination of unique genetic and novel pharmacologic tools, we show here that p110α 
mediates PI3K signaling in PanNETs and demonstrate that selective inhibition of p110α is 
sufficient to block PanNET progression. Hence, our data provide for the first time the 
rational to selectively target this isoform in this malignancy. Of note, further clinical 
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investigation is warranted to address whether these compound would be useful in the clinical 
setting and whether the therapeutic benefit for p110α inhibitors is justified considering 
toxicities observed in early clinical trials (hyperglycemia, gastrointestinal issues, and skin 
rash) (7).
Under the setting in which we analyzed the anti-tumor effect of selective p110α inhibition in 
the RIP1-Tag2 model, no resistance to treatment was observed. Interestingly, resistance to 
p110α inhibitors is related to loss of PTEN, which in turn results in p110β dependency (31). 
The observation that inhibition of all class I isoforms results in a similar anti-tumor response 
as selective inhibition of p110α in the RIP1-Tag2 model further supports the lack of 
resistance to the p110α inhibitor and no tumoral effects mediated by p110β. However, it 
remains to be elucidated whether long-term treatment of RIP1-Tag2 tumors with p110α 
selective inhibitors gives rise to resistance to treatment.
Our data support a dual anti-tumor effect of p110α intervention in PanNETs, namely anti-
vascular and pro-apoptotic, with the stromal effects being more prominent. p110α signaling 
is essential for blood vessels to grow in development and in tumors (29, 33). Therefore, 
p110α signaling in the endothelium is expected to account for tumor angiogenesis in 
PanNETs. PI3K signaling also promotes tumor angiogenesis by stimulating VEGF 
expression in tumor cells (10). Although VEGF is highly expressed in RIP1-Tag2 tumors 
(25), we have found that selective inhibition of p110α does not interfere with VEGF mRNA 
levels in these tumors. Together, our findings suggest that p110α activity stimulates tumor 
angiogenesis in RIP1-Tag2 tumors by regulating EC biology in a cell autonomous manner.
Selective inhibition of p110α also results in tumor cell death both in vivo and in vitro. Albeit 
significant, the impact of GDC-0326 on tumor cells in vitro is modest, which suggests that 
the apoptotic effect in the tumor observed in vivo upon GDC-0326 treatment is principally 
due to the reduction in tumor vascularity. Of note, this pro-apoptotic effect was confirmed by 
using BYL719, a p110α selective inhibitor currently being tested in the clinic for breast, 
head and neck and gastrointestinal tumors (7). Interestingly, traditional anti-angiogenic 
agents also lead to increased tumor cell death with no impact on tumor cell proliferation in 
RIP1-Tag2 tumors (38). In line with previous studies that treated RIP1-Tag2 mice with the 
mTOR inhibitor rapamycin (2), our results do not support a role for PI3K signaling in tumor 
cell proliferation. Our data differ from the findings of Valentino et al. (39) that showed that 
human neuroendocrine cells treated with BKM120, a pan PI3K inhibitor induced cell death 
and cell cycle arrest. Although, the reasons for these discrepancies are not clear at the 
moment, they may relate to the use of different doses of BKM120. Of note, when used at 
high doses (>1 µM), BKM120 shows some off-target effects, namely inhibiting microtubule 
polymerization. (40), which may explain why this compound inhibited cell proliferation.
An intriguing result of our study was that inhibiting all class I PI3K isoforms in RIP1-Tag2 
mice did not impact on tumor angiogenesis. This is surprising given that tumor cells express 
all class I PI3K isoforms and therefore redundancy function of PI3K isoforms in oncogenic 
signaling was expected, as has been documented in other tumor systems (7, 41). Class I 
PI3K isoforms have, however, pleiotropic roles in cancer which include both cancer intrinsic 
and extrinsic (stromal) functions, which underscores the complexity of targeting this 
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pathway in cancer (7, 10). The different angiogenic response observed upon GDC-0941 
(Fig. 2) vs. GDC-0326 (Fig. 6) in RIP1-Tag2 mice may thus relate to compensatory effects 
which result from inhibiting all class I PI3K isoforms (10, 34).
An important finding of our study is that p110α inhibition blocks tumor cell dissemination. 
Hyperactivation of PI3K/AKT has been associated with increased invasion, metastasis and 
poor prognosis (42, 43). Consistently, recent data have identified the PI3K/AKT hub as a 
key mediator of metastatic cancer development by regulating epithelial-mesenchymal 
transition (44). However, it is still unknown which PI3K isoform mediates this process. Our 
findings identify, for the first time, that the p110α isoform is a key mediator of tumor 
metastasis in vivo. This is in agreement with previous data, which showed that p110α 
regulates migration of metastatic tumor cells in vitro (45). Although the mechanism through 
which inhibition of p110α impedes metastasis in vivo it is not clear at the moment, it might 
relate to its effects on the tumor vessels. However, we cannot rule out that p110α may also 
regulate tumor cell intrinsic effects required for successfully colonization of secondary sites 
such as motility, polarity and strong survival capabilities (46). Further studies are warranted 
to mechanistically elucidate how p110α regulates tumor dissemination. Given that PanNETs 
are often diagnosed with metastatic disease, it would be relevant to also test whether 
targeting p110α can also inhibit an established metastatic lesion. Another interestingly 
unexplored aspect in this context would be to assess the effect of selective p110α targeting 
in cancer initiating cells.
The results of a phase III trial in PanNETs with everolimus have recently emerged showing 
beneficial effects but lacking statistical power (16), highlighting the need to continued need 
to improve therapies. Our data strongly indicate that p110α inhibition could be an 
alternative therapy to overcome limitations associated with everolimus. In addition to cell 
intrinsic tumor effects, targeting p110α in PanNETs also compromises tumor angiogenesis. 
In contrast, rapamycin treatment in RIP1-Tag2 mouse does not impact on tumor vessels 
which suggest reduced anti-tumor activity compared to treatment with p110α inhibitor. (2). 
Furthermore, PI3K acts upstream of mTOR and its inhibition may overcome mTOR-
dependent feedback inhibition of AKT (17–19). In a scenario of complete blockade of PI3K/
AKT, residual mTORC1 activity is enough to reduce the anti-tumor activity of p110α 
inhibition. Therefore, it is tempting to speculate that a combination of p110α and mTOR 
inhibitors in the treatment of PanNETs may cooperate to enhance the effectiveness of each 
compound alone. In line with this, combined RAD001 (rapalogue) and BEZ235 (a dual 
mTOR/PI3K inhibitor) treatment of neuroendocrine tumor cells in vitro overcomes 
resistance to RAD001 (47). Sunitinib, a tyrosine kinase inhibitor, is another targeted therapy 
currently being used in the clinic in PanNET patients. Mechanistically, sunitinib blocks, 
amongst others, VEGF signaling and in turn leads to vascular trimming and a delay in tumor 
progression (48). However, this inhibition is also accompanied by increased tumor 
dissemination in some preclinical tumor models, including PanNETs (49, 50), and effect that 
is overcome by c-Met inhibition (50). Based on the observation that PI3K signaling is 
activated downstream of c-Met, together with our data showing that selective inhibition of 
p110α inhibits metastasis, it is tempting to speculate that simultaneous inhibition of p110α 
and VEGF in PanNETs may also overcome limitations of VEGF targeted therapy.
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In conclusion, our work provides insights from mouse genetic and pharmacological studies 
to be translated into human therapy. Given that the RIP1-Tag2 tumor model used in this 
study has shown predictive value in demonstrating the clinical activity of targeted therapies, 
including everolimus and sunitinib (2, 25, 49), our data provide the rationale for the use of a 
p110α selective inhibitor to treat this disease.
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PanNETs are heterogeneous tumors, which has complicated the design of targeted 
therapies. By using a preclinical mouse model of PanNET, we report here on a new 
therapy to treat this malignancy, namely selective inhibition of the class I p110α PI3K 
isoform, and demonstrate that targeting this isoform inhibits tumor progression and 
metastasis. This is particularly relevant given that isoform-selective PI3K inhibitors are 
likely to exhibit lower toxicity compared to pan-PI3K inhibitors, and therefore higher 
drug doses which achieve complete inhibition of the pathway are expected to be 
tolerated. We also observe that p110α signaling regulates tumor cell dissemination, 
which provides a significant advance in understanding the role of PI3K signaling in 
cancer and opens new therapeutic opportunities for agents targeting this pathway.
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Figure 1. Activation of PI3K signaling in human and mouse PanNETs
A. Representative IHC images of human pancreatic islet cells, and neuroendocrine islet cell 
tumors for pAKT (S473) (above), pPRAS40 (T246) (middle) and pS6 (S240/4) (below) 
stainings. For islet cell tumors, representative negative and positive stainings are shown. 
Black lines delimit the normal islet. Scale bar: 100 µm. B. Quantification for the pAKT 
(S473), pPRAS40 (T246) and pS6 (S240/4) staining in a cohort of 40 human pancreatic 
neuroendocrine tumors. Black lines delimit the normal islet. C. Representative images of the 
RIP1-Tag2 mouse model normal islet cells, encapsulated pancreatic tumor, and invasive 
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carcinoma tumor stained with the PI3K pathway surrogates pAKT (S473), pPRAS40 (T246) 
and pS6 (S240/4). Dashed lines delimit the normal islet and the encapsulated tumor. Scale 
bar: 100 µm.
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Figure 2. Inhibition of class I PI3K isoforms impairs tumor progression
A. Western blot of AKT and S6 phosphorylation in individual RIP1-Tag2 tumors treated 
with vehicle or GDC-0941 for 3 h. B. Kaplan-Meier survival curves in tumor-bearing RIP1-
Tag2 mice (12 weeks) treated daily with vehicle (n=12) or GDC-0941 (100 mg/kg, n=12) for 
2 weeks. C. Total tumor burden analysis in 2-week treatment trial with vehicle (n=27) or 
GDC-0941 (100 mg/kg, n=12) starting at 12 weeks of age until 14 weeks of age. D. Gross 
pathology images of excised pancreas and livers from animals treated with vehicle or 
GDC-0941 for 2 weeks. Black arrow heads indicate tumors. E. Quantification of number of 
angiogenic “red” islet per mouse in vehicle (n=12) or GDC-0941 (n=11) for 2 weeks. F. 
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CD31 and DAPI-stained sections of vehicle- or GDC-0941-treated RIP1-Tag2 tumors. Scale 
bar: 100 µm. G. The graph shows quantification of vessel area per tumor viable area of 
RIP1-Tag2 tumors treated with vehicle (n=8) or GDC-0941 (n=23). Error bars are standard 
error of the mean.
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Figure 3. Genetic inactivation of p110α, but not p110β and p110δ, inhibits tumor growth
A. Analysis of p110 isoforms by western blot in βTC3 cells. B16 and Jurkat lysates were 
used as positive controls. B. Exponentially growing βTC3 cells were treated for 2 h with 
vehicle, GDC-0941 (1 µM), GDC-0326 (1 µM), TGX-221 (0.5 µM) or IC87114 (5 µM), 
followed by immunoblotting of total cell lysate using the indicated antibodies. C. Schematic 
illustration of the p110αD933A/WT mouse. D. Schematic illustration of the p110βD931A/WT 
mouse. E. Schematic illustration of the p110δD910A/WT mouse. F. Total tumor burden 
analysis in WT (n=19) and p110αD933A/WT (n=18) littermates at 14 weeks of age. G. Total 
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tumor burden analysis in WT (n=10) and p110βD931A/WT (n=14) littermates at 14 weeks of 
age. H. Total tumor burden analysis in wild-type (n=9) and p110δD910A/WT (n=24) 
littermates at 14 weeks of age. I. Western blot of AKT, S6 and 4EBP1 phosphorylation in 
individual RIP1-Tag2 tumors of WT and p110αD933A/WT littermates at 14 weeks of age. J. 
Bars show quantification of the relative immunoreactivity of pAKT normalized to total 
AKT. K. Western blot of AKT, S6 and 4EBP1 phosphorylation in individual RIP1-Tag2 
tumors of WT and p110βD931A/WT littermates at 14 weeks of age. L. Bars show 
quantification of the relative immunoreactivity of pAKT normalized to total AKT. M. 
Western blot of AKT, S6 and 4EBP1 phosphorylation in individual RIP1-Tag2 tumors of 
wild-type and p110δD910A/WT littermates at 14 weeks of age. N. Bars show quantification of 
the relative immunoreactivity of pAKT normalized to total AKT. Scale bar in A, C and E: 25 
µm. Error bars are standard error of the mean.
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Figure 4. p110α signaling promotes tumor angiogenesis
A. CD31 and DAPI-stained sections of WT and p110αD933A/WT RIP1-Tag2 tumors. B. The 
graph shows quantification of vessel area per tumor viable area of WT (n=17) and 
p110αD933A/WT (n=10) RIP1-Tag2 tumors. C. CD31 and DAPI-stained sections of WT and 
p110βD931A/WT RIP1-Tag2 tumors. D. The graph shows quantification of vessel area per 
tumor viable area of WT (n=5) and p110βD931A/WT (n=10) RIP1-Tag2 tumors. E. CD31 and 
DAPI-stained sections of WT and p110δD910A/WT RIP1-Tag2 tumors. F. The graph shows 
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quantification of vessel area per tumor viable area of WT (n=7) and p110δD910A/WT (n=16) 
RIP1-Tag2 tumors. Error bars are standard error of the mean.
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Figure 5. Pharmacological inhibition of p110α blocks tumor growth and metastasis
A. Western blot of AKT and S6 phosphorylation in individual RIP1-Tag2 tumors treated 
with vehicle or GDC-0326 for 3 h. B. Kaplan-Meier survival curves in tumor-bearing RIP1-
Tag2 mice (12 weeks) treated daily with vehicle (n=13) or GDC-0326 (12 mg/kg, n=13) for 
2 weeks. C. Total tumor burden analysis in 2-weeks treatment trial with vehicle (n=13) or 
GDC-0326 (12 mg/kg, n=13) starting at 12 weeks of age until 14 weeks of age. D. 
Histological analysis of liver and LN metastasis (Met) in RIP1-Tag2 mice treated with 
vehicle or GDC-0326 for 14 days starting at 12 weeks of age. Paraffin embedded sections 
were immunohistochemical stained for the tumor marker SV40 T antigen (brown). E. 
Quantification of the incidence of animals with microscopic liver micrometastasis and 
microscopic LN metastasis in the control (black bars) and GDC-0326 treated (red bars) 
treatment arms. F. Contingency table relating the number and percentage of animals in each 
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treatment/metastasis case. GDC-0326 treated mice show a statistic significant decrease in 
the incidence of liver micrometastasis and LN metastasis by the chi-square test.
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Figure 6. Inhibition of p110α results in cell intrinsic and extrinsic tumor effects
A. Quantification of number of angiogenic “red” islet per mouse in vehicle (n=13) or 
GDC-0326 (n=7) for 2 weeks. B. CD31 and DAPI-stained sections of vehicle- or 
GDC-0326-treated RIP1-Tag2 tumors. Scale bar: 100 µm. C. The graph shows 
quantification of vessel area per tumor viable area of RIP1-Tag2 tumors treated with vehicle 
(n=8) or GDC-0326- (n=22). D. Sections of tumors stained for TUNEL (green), CD31 (red) 
and DAPI (blue). Yellow asterisk marks TUNEL positive cells Scale bar: 50 µm. E. Bar 
graphs show quantification of apoptotic cells per viable tumor area in RIP1-Tag2 tumors 
treated with vehicle (n=10) or GDC-0326- (n=14). E. Cell viability of βTC3 cells following 
48 h in vitro treatment with vehicle, GDC-0941 (1 µM), GDC-0326 (1 µM), TGX-221 (0.5 
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µM) or IC87114 (5 µM), and analyzed by cleaved-caspase-3 immunoflorescence. Mean of 
eight independent experiments is shown. Error bars are standard error of the mean.
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